These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

237 related articles for article (PubMed ID: 25550126)

  • 1. Buprenorphine maintenance treatment retention improves nationally recommended preventive primary care screenings when integrated into urban federally qualified health centers.
    Haddad MS; Zelenev A; Altice FL
    J Urban Health; 2015 Feb; 92(1):193-213. PubMed ID: 25550126
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Integrating buprenorphine maintenance therapy into federally qualified health centers: real-world substance abuse treatment outcomes.
    Haddad MS; Zelenev A; Altice FL
    Drug Alcohol Depend; 2013 Jul; 131(1-2):127-35. PubMed ID: 23332439
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Long-term retention in Office Based Opioid Treatment with buprenorphine.
    Weinstein ZM; Kim HW; Cheng DM; Quinn E; Hui D; Labelle CT; Drainoni ML; Bachman SS; Samet JH
    J Subst Abuse Treat; 2017 Mar; 74():65-70. PubMed ID: 28132702
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Analysis of barriers to adoption of buprenorphine maintenance therapy by family physicians.
    DeFlavio JR; Rolin SA; Nordstrom BR; Kazal LA
    Rural Remote Health; 2015; 15():3019. PubMed ID: 25651434
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Barriers and facilitators to primary care or human immunodeficiency virus clinics providing methadone or buprenorphine for the management of opioid dependence.
    Turner BJ; Laine C; Lin YT; Lynch K
    Arch Intern Med; 2005 Aug 8-22; 165(15):1769-76. PubMed ID: 16087826
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Health care use and spending for Medicaid patients diagnosed with opioid use disorder receiving primary care in Federally Qualified Health Centers and other primary care settings.
    Peterson L; Murugesan M; Nocon R; Hoang H; Bolton J; Laiteerapong N; Pollack H; Marsh J
    PLoS One; 2022; 17(10):e0276066. PubMed ID: 36256662
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Harm Reduction Agencies as a Potential Site for Buprenorphine Treatment.
    Fox AD; Chamberlain A; Frost T; Cunningham CO
    Subst Abus; 2015; 36(2):155-60. PubMed ID: 25837290
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Treating opioid addiction with buprenorphine-naloxone in community-based primary care settings.
    Mintzer IL; Eisenberg M; Terra M; MacVane C; Himmelstein DU; Woolhandler S
    Ann Fam Med; 2007; 5(2):146-50. PubMed ID: 17389539
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Models for integrating buprenorphine therapy into the primary HIV care setting.
    Basu S; Smith-Rohrberg D; Bruce RD; Altice FL
    Clin Infect Dis; 2006 Mar; 42(5):716-21. PubMed ID: 16447120
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A comparison of characteristics and outcomes of opioid-dependent patients initiating office-based buprenorphine or methadone maintenance treatment.
    Fingerhood MI; King VL; Brooner RK; Rastegar DA
    Subst Abus; 2014; 35(2):122-6. PubMed ID: 24821346
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Initial strategies for integrating buprenorphine into HIV care settings in the United States.
    Sullivan LE; Bruce RD; Haltiwanger D; Lucas GM; Eldred L; Finkelstein R; Fiellin DA
    Clin Infect Dis; 2006 Dec; 43 Suppl 4():S191-6. PubMed ID: 17109306
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Buprenorphine maintenance treatment in a primary care setting: outcomes at 1 year.
    Soeffing JM; Martin LD; Fingerhood MI; Jasinski DR; Rastegar DA
    J Subst Abuse Treat; 2009 Dec; 37(4):426-30. PubMed ID: 19553061
    [TBL] [Abstract][Full Text] [Related]  

  • 13. HIV treatment access and scale-up for delivery of opiate substitution therapy with buprenorphine for IDUs in Ukraine--programme description and policy implications.
    Bruce RD; Dvoryak S; Sylla L; Altice FL
    Int J Drug Policy; 2007 Aug; 18(4):326-8. PubMed ID: 17689382
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Recent incarceration and buprenorphine maintenance treatment outcomes among human immunodeficiency virus-positive patients.
    Riggins DP; Cunningham CO; Ning Y; Fox AD
    Subst Abus; 2017; 38(3):297-302. PubMed ID: 27715904
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Drug test results as a predictor of retention among patients using buprenorphine in a comprehensive outpatient treatment program.
    Campbell MD; Kolodner G; Spencer RA; DuPont RL
    J Addict Dis; 2016; 35(4):315-324. PubMed ID: 26757093
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The potential role of buprenorphine in the treatment of opioid dependence in HIV-infected individuals and in HIV infection prevention.
    Altice FL; Sullivan LE; Smith-Rohrberg D; Basu S; Stancliff S; Eldred L
    Clin Infect Dis; 2006 Dec; 43 Suppl 4():S178-83. PubMed ID: 17109304
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Nine-year substance use treatment outcomes with buprenorphine for opioid use disorder in a federally qualified health center.
    Haddad M; Coman E; Bifulco L
    Drug Alcohol Depend; 2024 Apr; 257():111252. PubMed ID: 38484404
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Buprenorphine retention in primary care.
    Stein MD; Cioe P; Friedmann PD
    J Gen Intern Med; 2005 Nov; 20(11):1038-41. PubMed ID: 16307630
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Integrating Buprenorphine Into an Opioid Treatment Program: Tailoring Care for Patients With Opioid Use Disorders.
    Polydorou S; Ross S; Coleman P; Duncan L; Roxas N; Thomas A; Mendoza S; Hansen H
    Psychiatr Serv; 2017 Mar; 68(3):295-298. PubMed ID: 27745534
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effectiveness of buprenorphine maintenance treatment as compared to a syringe exchange program among buprenorphine misusing opioid-dependent patients.
    Aalto M; Visapää JP; Halme JT; Fabritius C; Salaspuro M
    Nord J Psychiatry; 2011 Sep; 65(4):238-43. PubMed ID: 21047194
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.